Acorda Therapeutics
15 Skyline Drive
Hawthorne
New York
10532
United States
Tel: 914-347-4300
Fax: 914-347-4560
Website: http://www.acorda.com/
Email: acorda@acorda.com
About Acorda Therapeutics
Acorda Therapeutics is a privately held biotechnology company developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS.Fampridine-SR acts to combat the effects of demyelination in the spinal cord. Myelin is the insulating sheath around nerve processes; when it is damaged due to trauma or disease, electrical impulses from the brain cannot be conducted past the demyelinated area. Fampridine-SR chemically blocks the exposed voltage-gated potassium channels, allowing the impulse from the brain to be conducted more normally past the area of damage. Fampridine is being studied in Phase 3 clinical trials to evaluate its efficacy in reducing spasticity in people with chronic spinal cord injury. Secondary endpoints in the study include evaluating its effect on bladder, bowel, and sexual function. The Company is also conducting a 152 patient, late Phase 2 clinical study in MS to evaluate Fampridine-SR's efficacy in walking speed and muscle strength.
Acorda's technology platform also includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies that have been shown to remyelinate the central nervous system in animal models, and the second is GGF2, a product of the neuregulin 1 gene. Preclinical studies have shown that GGF2 can stimulate the cell growth necessary to protect and regenerate damaged myelin. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain.
In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.
Key Management:
Ron Cohen, M.D., President and CEO Andrew R. Blight, Ph.D., Executive Vice President, Research & Development Mary Fisher, Vice President, Marketing and Strategic Planning Elliott A. Gruskin, Ph.D., Vice President, Research & Development Mitchell Katz, Ph.D., Vice President, Clinical Programs David Lawrence, Vice President, Finance Mark R. E. Pinney, C.F.A., Chief Financial Officer and Director Harold Safferstein, Ph.D., J.D., Vice President, Business Development
Last Updated: 05-09-03
598 articles about Acorda Therapeutics
-
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
7/22/2021
Acorda Therapeutics, Inc. announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A to commercialize INBRIJA® 33 mg in Spain.
-
Acorda Therapeutics Announces Repayment of Convertible Senior Notes
6/16/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on June 15, 2021, it repaid in full its 1.75% Convertible Senior Notes due 2021.
-
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
4/29/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2021 update and financial results on Thursday, May 6 at 4:30 p.m. ET.
-
Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”
4/12/2021
Culinary icon Zarela Martinez and Acorda Therapeutics (NASDAQ: ACOR) have partnered to launch “A Taste for Life with Zarela” to celebrate Parkinson’s Awareness Month. The video series showcases Zarela’s inspirational “building blocks” for living well with Parkinson’s disease (PD) and for healthy and delicious eating.
-
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
3/8/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the March 9th & 10th H.C. Wainwright Global Life Sciences Virtual Conference.
-
Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
3/4/2021
Acorda Therapeutics, Inc. provided a business update and reported its financial results for the fourth quarter and full year ended December 31, 2020.
-
Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
2/25/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter and year end 2020 update and financial results on Thursday, March 4 at 4:30 p.m. ET.
-
Acorda Therapeutics Announces Departure of Chief, Business Operations
2/19/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that David Lawrence, Chief, Business Operations and its principal accounting and financial officer, is resigning from the Company effective mid-March, 2021
-
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent
2/11/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent. Under the terms of the agreement, Catalent has paid Acorda $80 million in cash, resulting in expected net proceeds to Acorda of approximately $74 million after transaction fees and expenses and settlement of customary post-closing adjustments.
-
Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into “At The Market” Offering Agreement
1/13/2021
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash.
-
Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference
1/12/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care Conference on Thursday, January 14, at 5:20 PM ET
-
Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference
1/11/2021
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11 th -14 th H.C. Wainwright BIOCONNECT Virtual Conference. An audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com . For more information about the conference, please visit the event websi
-
Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split
12/31/2020
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company’s common stock will begin trading on a split-ad
-
Acorda Reports Third Quarter 2020 Financial Results
11/3/2020
Acorda Therapeutics, Inc. reported its financial results for the third quarter ended September 30, 2020.
-
Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020
10/27/2020
Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, November 3 at 4:30 p.m. ET.
-
Acorda Reports Second Quarter 2020 Financial Results
8/4/2020
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2020.
-
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
7/31/2020
Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on July 31, 2020, and stockholders approved proposals to authorize the Company’s Board of Directors to implement a reverse stock split, and to adjourn the meeting to provide stockholders with additional time to vote on Proposal One to approve an increase to the number of authorized shares of common stock.
-
Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020
7/28/2020
Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its second quarter 2020 update and financial results on Tuesday, August 4 at 4:30 p.m.
-
Acorda Reports First Quarter 2020 Financial Results and Provides Business Update
5/5/2020
Acorda Therapeutics, Inc. provided a business update and reported its financial results for the first quarter ended March 31, 2020.
-
Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020
4/28/2020
Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET..